Abstract |
A 67-year-old man with acute myeloid leukemia (AML) was treated with low-dose decitabine. He achieved a complete remission (CR) after two cycles of therapy, and he remained in remission during 1 year of treatment. He developed recurrent AML after discontinuation of decitabine. He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine.
|
Authors | Amanda F Cashen, Hollie Devine, John DiPersio |
Journal | American journal of hematology
(Am J Hematol)
Vol. 81
Issue 7
Pg. 543-5
(Jul 2006)
ISSN: 0361-8609 [Print] United States |
PMID | 16755561
(Publication Type: Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Decitabine
- Azacitidine
|
Topics |
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage)
- Azacitidine
(administration & dosage, analogs & derivatives)
- Decitabine
- Humans
- Leukemia, Myeloid, Acute
(prevention & control)
- Male
- Recurrence
- Remission Induction
- Time Factors
|